Geraldine Prizeman

Jun 14, 2024 | bmjopen.bmj.com | Niamh Byrne |Sarah McGarrigle |Geraldine Prizeman |Carol Spillane

DiscussionThis scoping review has mapped evidence relevant to cancer risk-management DAs that are applicable to female BRCA mutation carriers without a personal history of cancer. Specifically, we have identified and described the features of cancer risk-management DAs for this population and reported on the efficacy testing of these DAs where this has been conducted.